$AVCNF News
Last published 1w ago
- 1w agoAVCNFAvicanna to Report Q3 2026 Results and Host Call on Nov. 12GlobeNewswireTORONTO, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. ("Avicanna" or the "Company") (TSX:AVCN) (OTCQB:AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and
- 1w agoAVCNFAvicanna Announces Closing of Non-Brokered Private Placement of Non-Convertible Debenture UnitsGlobeNewswireNOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAWS TORONTO, Oct.
- 3w agoAVCNFAvicanna Transitions US Listing to OTCQBGlobeNewswireTORONTO, Oct. 16, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. ("Avicanna" or "Company) (TSX:AVCN) (OTCQB:AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and
- 2mo agoAVCNFAvicanna Announces Closing of Strategic Non-Brokered Private PlacementGlobeNewswireTORONTO, Aug. 19, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. ("Avicanna" or the "Company") (TSX:AVCN) (OTCQX:AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing and
- 2mo agoAVCNFAvicanna Reports Q2 2026 Financial ResultsGlobeNewswireGross margin improves to 57%, supported by 48% quarterly growth in proprietary product salesQUIX™ rapid-onset portfolio prepared for Q3 launch with more than 35 commercial listings secured TORONTO, Aug. 14, 2026
- 3mo agoAVCNFAvicanna Introduces QUIX™ Rapid-Onset Medical Cannabis PortfolioGlobeNewswireInitial Medical Cannabis SKUs, Including Rapid-Onset Capsules and Soft Chews, Planned for Q3 2026 Improving Patient Access with Accurately Dosed, Rapid-Onset and Non-Combustible Formats TORONTO, July 16, 2026 (GLOBE
- 4mo agoAVCNFAvicanna Announces Promotion of Nick Hilborn CPA CA to Chief Financial OfficerGlobeNewswireTORONTO, June 30, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. ("Avicanna" or "Company) (TSX:AVCN) (OTCQX:AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and
- 5mo agoAVCNFAvicanna Announces Closing of Non-Brokered Private PlacementGlobeNewswireNOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAWS TORONTO, June
- 6mo agoAVCNFAvicanna Reports Q1 2026 Financial StatementsGlobeNewswireRecord revenue and gross profits driven by Canadian commercial growth and proprietary product expansionContinued advancement of pharmaceutical pipeline, medical affairs initiatives and international platform TORONTO,
- 6mo agoAVCNFAvicanna Announces Results of Annual General and Special MeetingGlobeNewswireTORONTO, May 08, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. ("Avicanna" or "Company) (TSX:AVCN) (OTCQX:AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and commercialisation of
- 6mo agoAVCNFAvicanna Announces Change in Board of DirectorsGlobeNewswireTORONTO, May 01, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. ("Avicanna" or the "Company) (TSX:AVCN) (OTCQX:AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and commercialisation of
- 6mo agoAVCNFAvicanna Welcomes Initial U.S. Rescheduling of Medical Cannabis & Provides Scientific UpdateGlobeNewswireRescheduling aligns with Avicanna's established pharmaceutical and medical cannabis strategyRescheduling further supports advancement of R&D, clinical development, and medical affairs initiatives TORONTO, April 28,
- 6mo agoAVCNFAnnual General and Special Meeting of Shareholders to be held May 7, 2026GlobeNewswireTORONTO, April 21, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. ("Avicanna" or the "Company) (TSX:AVCN) (OTCQX:AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and commercialisation of
- 6mo agoAVCNFAvicanna Announces Agenda for 6th Annual Clinical Symposium on Cannabinoid TherapeuticsGlobeNewswireAn established forum for evidence-based clinical discussion, interdisciplinary dialogue, and patient considerationsEvent is expanded to two days, live and virtual on June 11-12, 2026, at the MaRS Discovery District,
- 7mo agoAVCNFAvicanna Announces Changes to its Board of DirectorsGlobeNewswireTORONTO, April 06, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. ("Avicanna" or the "Company") (TSX:AVCN) (OTCQX:AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and commercialisation of
- 7mo agoAVCNFAvicanna Reports Full Year 2025 Audited Financial StatementsGlobeNewswireAchieved positive adjusted EBITDA in Q4 2025 and near break-even $(0.29) million for the full year Advancements across business units, R&D, and clinical development to support scale and international growth TORONTO,
- 7mo agoAVCNFAvicanna Subsidiary SMGH Completes First Commercial Export to AustraliaGlobeNewswireThis marks the first commercial export of organic certified flower for SMGH The export represents the 21st market for SMGH and 24th market for all Avicanna products TORONTO, March 26, 2026 (GLOBE NEWSWIRE) -- Avicanna
- 8mo agoAVCNFAvicanna Announces Sponsorship of University of Calgary THC Dose Finding Clinical TrialGlobeNewswireTORONTO, March 16, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. ("Avicanna" or the "Company") (TSX:AVCN) (OTCQX:AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing, and commercialization
- 9mo agoAVCNFAvicanna Announces Closing of Non-Brokered Private PlacementGlobeNewswireNOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAWS TORONTO, Feb.
- 9mo agoAVCNFAvicanna Announces Medical Cannabis Real World Evidence Results and PublicationGlobeNewswireTORONTO, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. ("Avicanna" or the "Company") (TSX:AVCN) (OTCQX:AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing, and commercialization
- 10mo agoAVCNFAvicanna Announces Changes to its Board of DirectorsGlobeNewswireTORONTO, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Avicanna Inc. ("Avicanna" or "Company") (TSX:AVCN) (OTCQX:AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing, and commercialization of
- 10mo agoAVCNFAvicanna Applauds President Trump's Executive Order to Reclassify Cannabis & Provides Scientific UpdateGlobeNewswireAvicanna's evidence-based pathway for cannabinoid-based medicine aligns with the executive order. Avicanna's 2025 advances across R&D, clinical development, and medical affairs. TORONTO, Dec. 19, 2025 (GLOBE
- 11mo agoAVCNFAvicanna Announces Pre-Clinical Data Supporting Enhanced Absorption and Patent Filing for Novel Oral Delivery PlatformGlobeNewswirePwdRx novel drug delivery platform demonstrated superior bioavailability and accelerated absorption of cannabinoids in preclinical studies Provisional patent application on the novel drug delivery platform which can be
- 12mo agoAVCNFAvicanna Reports Q3 2025GlobeNewswireTORONTO, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Avicanna Inc. ("Avicanna" or "Company") (TSX:AVCN) (OTCQX:AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and commercialization of
- 1y agoAVCNFAvicanna Announces Change in CFOGlobeNewswireTORONTO, Sept. 12, 2025 (GLOBE NEWSWIRE) -- Avicanna Inc. ("Avicanna" or the "Company") (TSX:AVCN) (OTCQX:AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing and commercialisation
- 1y agoAVCNFAvicanna Subsidiary Completes Export of CBD Dominant Cannabis Flower into SwitzerlandGlobeNewswireThis marks the first export of organic certified flower for SMGH, 20th international market for Aureus branded products and 23rd market for all Avicanna products TORONTO, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Avicanna
- 1y agoAVCNFAvicanna Reports Q2 2025GlobeNewswireTORONTO, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Avicanna Inc. ("Avicanna" or "Company") (TSX:AVCN) (OTCQX:AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and commercialization of
- 1y agoAVCNFAvicanna Announces US Patent and Trademark Office Issuance of New PatentGlobeNewswireUSPTO Issues Patent No. US 12,343,315 B2 covering topical cannabinoid compositions for clear skin TORONTO, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Avicanna Inc. ("Avicanna" or "Company) (TSX:AVCN) (OTCQX:AVCNF) (FSE: 0NN) a
- 1y agoAVCNFAvicanna Announces Closing of Non-Brokered Private PlacementGlobeNewswireNOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAWS TORONTO, July
- 1y agoAVCNFAvicanna Announces Results of Annual General MeetingGlobeNewswireTORONTO, June 30, 2025 (GLOBE NEWSWIRE) -- Avicanna Inc. ("Avicanna" or the "Company) (TSX:AVCN) (OTCQX:AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and commercialization of
- 1y agoAVCNFAvicanna Announces Sponsorship of Pilot Phase II Clinical Study Osteoarthritis PainGlobeNewswireTORONTO, May 20, 2025 (GLOBE NEWSWIRE) -- Avicanna Inc. ("Avicanna" or "Company") (TSX:AVCN) (OTCQX:AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing, and commercialization of
- 1y agoAVCNFAvicanna Reports Q1 2025 Results and First Profitable QuarterGlobeNewswireTORONTO, May 15, 2025 (GLOBE NEWSWIRE) -- Avicanna Inc. ("Avicanna" or the "Company) (TSX:AVCN) (OTCQX:AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and commercialization of
- 1y agoAVCNFAvicanna Announces Revocation of Management Cease Trade OrderGlobeNewswireTORONTO, April 16, 2025 (GLOBE NEWSWIRE) -- Avicanna Inc. ("Avicanna" or "Company") (TSX:AVCN) (OTCQX:AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing, and commercialization of
- 1y agoAVCNFAvicanna Reports Full Year 2024 Audited Financial StatementGlobeNewswire2024 Revenue of $25.5M, a 52% increase from 2023 Consolidated Gross Margins of 51%, Gross Profits of $12.9M, a 94% increase from 2023 TORONTO, April 14, 2025 (GLOBE NEWSWIRE) -- Avicanna Inc. ("Avicanna" or the
- 1y agoAVCNFAvicanna Announces Receipt of Management Cease Trade Order and Provides Bi-Weekly Status UpdateGlobeNewswireAuditor Licensing & Personnel Issues Delays Issuance of Audit OpinionThe Company expects to file within 1 week TORONTO, April 07, 2025 (GLOBE NEWSWIRE) -- Avicanna Inc. ("Avicanna" or "Company") (TSX:AVCN)
- 1y agoAVCNFAvicanna Announces its 5th Medical Symposium on Cannabinoid-based MedicineGlobeNewswireBridging Science and Clinical Practice: A Gathering of Thought Leaders in Cannabinoid MedicineLive and Virtual Symposium on June 6th, 2025, at the MaRS Discovery District, Toronto TORONTO, April 07, 2025 (GLOBE
- 1y agoAVCNFAvicanna Announces Late Filing of Financial Statements and Application for Management Cease Trade OrderGlobeNewswireAuditor Licensing & Personnel Issues Delays Issuance of Audit OpinionThe Company expects to file within 2 weeks TORONTO, March 31, 2025 (GLOBE NEWSWIRE) -- Avicanna Inc. ("Avicanna" or "Company") (TSX:AVCN)
- 1y agoAVCNFAvicanna To Hold Full Year 2024 Earnings Conference CallGlobeNewswireTORONTO, March 18, 2025 (GLOBE NEWSWIRE) -- Avicanna Inc. ("Avicanna" or "Company") (TSX:AVCN) (OTCQX:AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing, and commercialization of
- 1y agoAVCNFAvicanna Announces Scientific and Medical Affairs Collaboration with Vectura Fertin PharmaGlobeNewswireTORONTO, Jan. 16, 2025 (GLOBE NEWSWIRE) -- Avicanna Inc. ("Avicanna" or the "Company") (TSX:AVCN) (OTCQX:AVCNF) (FSE: 0NN), a commercial stage, international biopharmaceutical company focused on the commercialization
- 1y agoAVCNFAvicanna Completes First Delivery of Proprietary Topical Products to Multinational Pharmaceutical CompanyGlobeNewswireTORONTO, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. ("Avicanna" or the "Company") (TSX:AVCN) (OTCQX:AVCNF) (FSE: 0NN), a commercial stage, international biopharmaceutical company focused on the commercialization
- 1y agoAVCNFAvicanna Reports Q3 2024GlobeNewswire9-month revenue of $18.8 million, representing a 75% increase from 2023. Consolidated Gross Margins of 57%, during Q3 2024. TORONTO, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. ("Avicanna" or the "Company")
- 2y agoAVCNFAvicanna Announces Closing of Non-Brokered Private PlacementGlobeNewswireNOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAWS TORONTO, Nov.
- 2y agoAVCNFAvicanna Announces Medical Cannabis Real World Evidence Study through MyMedi.caGlobeNewswireTORONTO, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. ("Avicanna" or the "Company) (TSX:AVCN) (OTCQX:AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and commercialization of
- 2y agoAVCNFAvicanna Announces Repayment of DebenturesGlobeNewswireTORONTO, Aug. 30, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. ("Avicanna" or the "Company") (TSX:AVCN) (OTCQX:AVCNF) (FSE: 0NN), a commercial stage, international biopharmaceutical company focused on the development
- 2y agoAVCNFAvicanna Announces Closing of Non-Brokered Private PlacementGlobeNewswireNOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAWS TORONTO, Aug.
- 2y agoAVCNFAvicanna Announces United States Patent and Trademark Office Issuance of Patent on Topical TechnologyGlobeNewswireUSPTO issues Patent No. US 20230025693A1 ("Patent") that covers Avicanna's deep penetrating topicalcannabinoid composition and methods for treating musculoskeletal inflammation and pain TORONTO, Aug. 27, 2024
- 2y agoAVCNFAvicanna Subsidiary Completes Export of Aureus Branded CBG into DenmarkGlobeNewswireTORONTO, Aug. 15, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. ("Avicanna" or the "Company) (TSX:AVCN) (OTCQX:AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and commercialisation of
- 2y agoAVCNFAvicanna Reports Q2 2024GlobeNewswireQ2 2024 revenue of $6.1 million an increase of 85% over Q2 2023Completion of two real world evidence trials on Epidermolysis Bullosa and Musculoskeletal Pain TORONTO, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc.
- 2y agoAVCNFAvicanna Announces Changes of AuditorsGlobeNewswireTORONTO, Aug. 02, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. ("Avicanna" or the "Company) (TSX:AVCN) (OTCQX:AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and commercialization of
- 2y agoAVCNFAvicanna Subsidiary Completes Export of Aureus Branded CBG into SingaporeGlobeNewswireThis marks the first export into Asia, the 18th international market for Aureus branded products and 21st market for all Avicanna products TORONTO, July 11, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. ("Avicanna" or the